These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38679237)

  • 1. Experience of dupilumab treatment in inherited epidermolysis bullosa: A short series.
    Bellon N; Bataille P; Bonigen J; Charbit-Henrion F; Dietrich C; Polivka L; Hadj-Rabia S; Leite de Moraes M; Bodemer C
    J Am Acad Dermatol; 2024 Aug; 91(2):373-376. PubMed ID: 38679237
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of epidermolysis bullosa pruriginosa-associated pruritus with dupilumab.
    Shehadeh W; Sarig O; Bar J; Sprecher E; Samuelov L
    Br J Dermatol; 2020 Jun; 182(6):1495-1497. PubMed ID: 31899820
    [No Abstract]   [Full Text] [Related]  

  • 3. Dupilumab improves itch and blistering in different subtypes of epidermolysis bullosa.
    Gewert S; Davidovic M; Has C; Kiritsi D
    J Dtsch Dermatol Ges; 2024 Aug; 22(8):1139-1144. PubMed ID: 38679781
    [No Abstract]   [Full Text] [Related]  

  • 4. Pruritus Anesis in Dystrophic Epidermolysis Bullosa Pruriginosa with Dupilumab.
    Yang DY; Jing WW; Liu X; Li L; Lu T; Li XL
    Adv Skin Wound Care; 2024 Feb; 37(2):1-4. PubMed ID: 38241457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of epidermolysis bullosa pruriginosa by dupilumab.
    Wu XG; Yan S; Jiang JQ; Zhou TT; Fang X; Yang H; Bai XM; Wang H; Luo X
    J Dermatol; 2023 Jun; 50(6):837-842. PubMed ID: 36694424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dupilumab in the treatment of dystrophic epidermolysis bullosa: off-label use in a pediatric patient.
    Xará J; Relvas M; Figueiredo C; Calvão J; Batista M; Ramos L
    Int J Dermatol; 2023 Dec; 62(12):e617-e618. PubMed ID: 37622659
    [No Abstract]   [Full Text] [Related]  

  • 7. Successful Control of Recalcitrant Pruritus in Epidermolysis Bullosa Pruriginosa With Dupilumab.
    Roque Quintana B; Piqué Durán E; Pérez Cejudo JA
    Actas Dermosifiliogr; 2024 Feb; 115(2):184-186. PubMed ID: 36871818
    [No Abstract]   [Full Text] [Related]  

  • 8. Dominant dystrophic epidermolysis bullosa is associated with glycolytically active GATA3+ T helper 2 cells which may contribute to pruritus in lesional skin.
    Aala WJF; Hou PC; Hong YK; Lin YC; Lee YR; Tu WT; Papanikolaou M; Benzian-Olsson N; Onoufriadis A; I Chen Harn H; Hwang DY; Cheng SM; Lu K; Chen PC; McGrath JA; Hsu CK
    Br J Dermatol; 2024 Jul; 191(2):252-260. PubMed ID: 38477474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of epidermolysis bullosa simplex with dupilumab.
    Sun X; Zhang J; Yang Q; Lin J
    J Dermatol; 2024 Apr; 51(4):e131-e132. PubMed ID: 37950437
    [No Abstract]   [Full Text] [Related]  

  • 10. Epidermolysis bullosa pruriginosa treated with dupilumab.
    Zhou AG; Little AJ; Antaya RJ
    Pediatr Dermatol; 2021 Mar; 38(2):526-527. PubMed ID: 33336814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of aprepitant for refractory pruritus in patients with epidermolysis bullosa and atopic dermatitis: A retrospective study.
    Hartzell CJ; Szabova A; Collins AB; Morel AN; Mijatovic D; Goldschneider KR
    Pediatr Dermatol; 2024; 41(5):819-821. PubMed ID: 39049669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case of junctional epidermolysis bullosa intermediate with collagen XVII deficiency treated with dupilumab.
    Zhang L; Wang S; Chen Q; Xiang L
    J Dermatolog Treat; 2023 Dec; 34(1):2253943. PubMed ID: 37968922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Phenytoin therapy in recessive dystrophic epidermolyses (epidermolysis bullosa dystrophica type Hallopeau-Siemens and epidermolysis bullosa dystrophica inversa)].
    Wirth H; Nesch A; Ostapowicz B; Anton-Lamprecht I
    Z Hautkr; 1983 Apr; 58(8):555-74. PubMed ID: 6858283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dupilumab as a novel therapy for epidermolysis bullosa pruriginosa.
    Shao L; Zhong DQ; Liu YM; Wang JQ
    Int J Dermatol; 2023 Oct; 62(10):e542-e545. PubMed ID: 37326291
    [No Abstract]   [Full Text] [Related]  

  • 15. A case of dystrophic epidermolysis bullosa pruriginosa treated with dupilumab.
    Caroppo F; Milan E; Giulioni E; Belloni Fortina A
    J Eur Acad Dermatol Venereol; 2022 May; 36(5):e365-e367. PubMed ID: 34927769
    [No Abstract]   [Full Text] [Related]  

  • 16. Amelioration of dystrophic epidermolysis bullosa pruriginosa symptoms with dupilumab: A case report.
    Wang Y; Zhou M; Zhang L; Zheng S; Hong Y; Gao XH
    Dermatol Ther; 2021 Nov; 34(6):e15130. PubMed ID: 34528352
    [No Abstract]   [Full Text] [Related]  

  • 17. Carcinoembryonic antigen: increased plasma levels in recessive epidermolysis bullosa.
    Rochman H; Cooper M; Esterly NB; Bauer EA
    J Invest Dermatol; 1979 May; 72(5):262-3. PubMed ID: 458187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proceedings: Epidermolysis bullosa.
    Trent WG; Newton D; Rosenberg EW
    Arch Dermatol; 1976 Feb; 112(2):256. PubMed ID: 962355
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of Epidermolysis bullosa acquisita with dupilumab.
    Diehl R; Kiritsi D; Schauer F
    J Dtsch Dermatol Ges; 2024 Oct; 22(10):1417-1419. PubMed ID: 39094124
    [No Abstract]   [Full Text] [Related]  

  • 20. Inherited epidermolysis bullosa and the risk of death from renal disease: experience of the National Epidermolysis Bullosa Registry.
    Fine JD; Johnson LB; Weiner M; Stein A; Cash S; DeLeoz J; Devries DT; Suchindran C;
    Am J Kidney Dis; 2004 Oct; 44(4):651-60. PubMed ID: 15384016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.